1 Five (15%)
patients had 11 grade 3 treatment-related adverse events; no
2 Six (3%)
patients had 11 serious adverse events: one (2%) patient in t
3 ment assignment accounting for nonindependence of eyes when
patients had 2 uveitic eyes.
4 edly reduced rod and cone responses, but nonsyndromic USH2A
patients had 30 Hz-flicker electroretinogram amplitudes that
5 Within 30 days, CABG
patients had a 25-fold, a 26-fold, and a 18-fold higher risk
6 11 (18%) of 60 assessable
patients had a confirmed objective response, including ten (3
7 Younger
patients had a higher likelihood of complete clinical success
8 A total of 283
patients had a serious infection; the incidence rates with 95
9 36 (10%) of 370
patients had a serious treatment-related adverse event.
10 Eligible
patients had a streptococcal PJI that was managed with DAIR.
11 At implant, 99.5% of
patients had a successful conversion of induced ventricular t
12 A total of 31.1% of all
patients had an ophthalmic procedure, pars plana vitrectomy (
13 Eleven of the 434
patients had another infection within 6 months, but only 4 of
14 Eligible
patients had been enrolled at one centre in the AURA study, h
15 (median age, 63 years; 286 [32%] women) of the planned 1100
patients had been enrolled with follow-up for a median of 15
16 the current study had severe ocular abnormalities, and all
patients had bilateral involvement.
17 CLIPPERS
patients had brainstem predominant perivascular gadolinium en
18 e BMI at surgery was 13.83 (SD 1.49) and 14 (88%) of the 16
patients had comorbid mood disorders, anxiety disorders, or b
19 One hundred and eight
patients had cysts </=1.5 cm for more than 5 years of follow-
20 izumab; IQR 40.8-59.3 for chemotherapy), at which point 415
patients had died (214 in the chemotherapy group and 201 in t
21 g clones within the same patient, 30 (68%) of 44 individual
patients had different levels of responses within the M1 and
22 Concluding, the present study found that OCD
patients had difficulties with the deactivation of DMN even w
23 Seventeen
patients had either device thrombosis or ischemic stroke.
24 One-third of CSU
patients had elevated levels of CRP.
25 A total of 131 of 740
patients had geriatric complications, and 114 of 740 patients
26 26 (39%) of 44
patients had grade 3 adverse events, but no grade 4 events we
27 Fifty-five percent of
patients had grade 3 or 4 neurologic toxicities that complete
28 Six
patients had hepatitis B surface antibody (anti-HBs) titres a
29 edian number of previous lines of therapy was two (2-5), 38
patients had high-risk cytogenetics, 17 were unresponsive to
30 In the health registry study, moderate-severe AD
patients had increased risk of antidepressant and anxiolytic
31 BAL fluid from asthmatic
patients had increased TSLP but not IL-7 levels.
32 5 at the Massachusetts Eye and Ear Infirmary, 48 eyes of 44
patients had keratoprosthesis type II implanted by 2 surgeons
33 At follow-up, triage
patients had lower health-related quality of life than an age
34 In contrast, 47.9% aCT
patients had mastectomies with 7.3% BLM.
35 More than one third of U.S. HIV
patients had missed opportunities to initiate hepatitis B vac
36 Reduced starting dose sorafenib
patients had more Barcelona Clinic Liver Cancer stage D ( P <
37 AMR-positive
patients had more dnDSA with a significant higher frequency o
38 Importantly, simultaneous
patients had more renal vascular thromboses (4.4% vs 1.3% tx
39 ICD-positive
patients had more severe depression, poorer sleep quality and
40 Although we found evidence that high-risk
patients had more to gain from treatment, we were unable to r
41 Surviving
patients had,
on average, large improvements in health status
42 Eleven (4%) of the 274
patients had PHD after treatment with (177)Lu-DOTATATE: 8 pat
43 Two (1%) of 166
patients had serious adverse events; neither were considered
44 BDG
patients had significantly higher cerebral blood flow than di
45 Compared with CLF patients, PCLD
patients had significantly lower bilirubin and international
46 In the PRT setting of locally advanced RC, SRCC
patients had significantly worse prognosis.
47 ction (stages I and II) was achieved in 32 patients, and 28
patients had stage III or IV disease.
48 of 740 patients had geriatric complications, and 114 of 740
patients had surgical complications; 187 of 740 patients (25.
49 Patients had undergone imaging with various combinations of c
50 Twenty-two
patients had XLP (9.7%; 10 male and 12 female patients), and